These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 3191937)
21. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease. Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369 [TBL] [Abstract][Full Text] [Related]
23. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
24. Melphalan hydrochloride for the treatment of multiple myeloma. Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983 [TBL] [Abstract][Full Text] [Related]
25. [Polychemotherapy versus melphalan-prednisone in multiple myeloma]. Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590 [No Abstract] [Full Text] [Related]
27. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma. Wilson K; Shelley W; Belch A; Brandes L; Bergsagel D; Klimo P; White D; Willan A Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060 [TBL] [Abstract][Full Text] [Related]
28. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. Shulman LN; Buswell L; Kalish LA; Coleman CN Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):541-3. PubMed ID: 8005813 [TBL] [Abstract][Full Text] [Related]
29. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852 [TBL] [Abstract][Full Text] [Related]
30. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241 [TBL] [Abstract][Full Text] [Related]
31. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT; J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703 [TBL] [Abstract][Full Text] [Related]
32. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200 [TBL] [Abstract][Full Text] [Related]
33. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M; Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576 [TBL] [Abstract][Full Text] [Related]
34. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228 [TBL] [Abstract][Full Text] [Related]
35. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252 [TBL] [Abstract][Full Text] [Related]
36. Renal function in the elimination of oral melphalan in patients with multiple myeloma. Adair CG; Bridges JM; Desai ZR Cancer Chemother Pharmacol; 1986; 17(2):185-8. PubMed ID: 3719900 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428 [TBL] [Abstract][Full Text] [Related]